全文获取类型
收费全文 | 1022篇 |
免费 | 68篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 25篇 |
妇产科学 | 9篇 |
基础医学 | 108篇 |
口腔科学 | 6篇 |
临床医学 | 87篇 |
内科学 | 192篇 |
皮肤病学 | 13篇 |
神经病学 | 97篇 |
特种医学 | 30篇 |
外科学 | 127篇 |
综合类 | 1篇 |
预防医学 | 26篇 |
眼科学 | 26篇 |
药学 | 215篇 |
中国医学 | 51篇 |
肿瘤学 | 51篇 |
出版年
2023年 | 7篇 |
2022年 | 10篇 |
2021年 | 15篇 |
2020年 | 7篇 |
2019年 | 13篇 |
2018年 | 15篇 |
2017年 | 24篇 |
2016年 | 12篇 |
2015年 | 33篇 |
2014年 | 36篇 |
2013年 | 37篇 |
2012年 | 52篇 |
2011年 | 61篇 |
2010年 | 31篇 |
2009年 | 36篇 |
2008年 | 64篇 |
2007年 | 47篇 |
2006年 | 62篇 |
2005年 | 61篇 |
2004年 | 64篇 |
2003年 | 44篇 |
2002年 | 40篇 |
2001年 | 33篇 |
2000年 | 30篇 |
1999年 | 27篇 |
1998年 | 11篇 |
1997年 | 10篇 |
1996年 | 9篇 |
1995年 | 2篇 |
1994年 | 11篇 |
1993年 | 7篇 |
1992年 | 29篇 |
1991年 | 25篇 |
1990年 | 16篇 |
1989年 | 16篇 |
1988年 | 11篇 |
1987年 | 14篇 |
1986年 | 12篇 |
1985年 | 11篇 |
1984年 | 8篇 |
1983年 | 7篇 |
1982年 | 6篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1975年 | 10篇 |
1972年 | 2篇 |
1971年 | 1篇 |
排序方式: 共有1091条查询结果,搜索用时 218 毫秒
31.
32.
Giovanni Landoni Tiziana Bove Andrea Székely Marco Comis Reitze N. Rodseth Daniela Pasero Martin Ponschab Marta Mucchetti Maria L. Azzolini Fabio Caramelli Gianluca Paternoster Giovanni Pala Luca Cabrini Daniele Amitrano Giovanni Borghi Antonella Capasso Claudia Cariello Anna Carpanese Rinaldo Bellomo 《Journal of cardiothoracic and vascular anesthesia》2013,27(6):1384-1398
33.
34.
Diamanti Luca Borrelli Paola Dubbioso Raffaele Capasso Margherita Morelli Claudia Lunetta Christian Petrucci Antonio Mora Gabriele Volanti Paolo Inghilleri Maurizio Tremolizzo Lucio Mandrioli Jessica Mazzini Letizia Vedovello Marcella Siciliano Gabriele Filosto Massimiliano Mat Sabrina Montomoli Cristina 《Neurological sciences》2022,43(5):3195-3200
Neurological Sciences - Dysphagia is a common symptom during the trajectory of ALS, and it can significantly impact on the quality of life and prognosis of patients. Nowadays, no specific tool for... 相似文献
35.
36.
Piero Ruggenenti Barbara Ruggiero Paolo Cravedi Marina Vivarelli Laura Massella Maddalena Marasà Antonietta Chianca Nadia Rubis Bogdan Ene-Iordache Michael Rudnicki Rosa Maria Pollastro Giovambattista Capasso Antonio Pisani Marco Pennesi Francesco Emma Giuseppe Remuzzi 《Journal of the American Society of Nephrology : JASN》2014,25(4):850-863
The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic, multicenter, off-on trial (ClinicalTrials.gov #) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ≥2 recurrences over the previous year and were in steroid-induced remission for ≥1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m2 intravenously). At 1 year, all patients were in remission: 18 were treatment-free and 15 never relapsed. Compared with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median number of relapses decreased from 2.5 (interquartile range [IQR], 2–4) to 0.5 (IQR, 0–1; P<0.001) during 1 year of follow-up. Reduction was significant across subgroups (children, adults, MCD/MesGN, and FSGS; P<0.01). After rituximab, the per-patient steroid maintenance median dose decreased from 0.27 mg/kg (IQR, 0.19–0.60) to 0 mg/kg (IQR, 0–0.23) (P<0.001), and the median cumulative dose to achieve relapse remission decreased from 19.5 mg/kg (IQR, 13.0–29.2) to 0.5 mg/kg (IQR, 0–9.4) (P<0.001). Furthermore, the mean estimated GFR increased from 111.3±25.7 to 121.8±29.2 ml/min per 1.73 m2 (P=0.01), with the largest increases in children and in FSGS subgroups. The mean height z score slope stabilized in children (P<0.01). Treatment was well tolerated. Rituximab effectively and safely prevented recurrences and reduced the need for immunosuppression in steroid-dependent or frequently relapsing nephrotic syndrome, and halted disease-associated growth deficit in children.Idiopathic nephrotic syndrome (NS) in children and young adults is almost invariably the clinical counterpart of a continuum of glomerular diseases ranging from the relatively frequent minimal change disease (MCD) and the less frequent mesangial proliferative GN (MesGN), which are predominantly observed in children, to the relatively uncommon FSGS that is observed more frequently in adult patients. NCT009818381 In a small minority of patients that are generally resistant to immunosuppressive therapies, the disease is due to molecular defects of one of the podocyte genes.2 In all of the other cases, it appears to be immune-mediated, but the pathophysiologic process underlying glomerular injury remains poorly understood.3Independent of the underlying renal pathology, prednisone continues to be the cornerstone treatment at disease onset, achieving remission within 4 weeks in approximately 90% of children with MCD and in 20%–60% of those with FSGS.4,5 However, 60%–70% of patients relapse after steroid tapering or withdrawal, and most require repeat courses of prednisone to achieve remission of recurrent episodes and/or the addition of other immunosuppressive medications, such as calcineurin inhibitors, mycophenolate mofetil, or alkylating agents, to reduce the number of relapses and prevent major side effects of steroid treatment.6 According to their relapse rate, these patients are classically labeled as “steroid-dependent” or “frequently relapsing”. In these patients, serious adverse effects of treatment associate with complications of relapsing episodes of heavy proteinuria. These are the patients in most urgent need of more effective and safer treatment.The possibility of a specific and, hopefully, safer approach to patients with steroid-dependent or frequently relapsing NS emerged in 2004 when the B cell–depleting mAb rituximab was reported to induce remission of proteinuria in a child with frequently relapsing NS secondary to MCD who had received this medication to cure a supervened idiopathic thrombocytopenic purpura.7 Subsequent uncontrolled observations found some effect of rituximab in patients with steroid-dependent or frequently relapsing MCD,8–11 suggesting that B-cell immunity could play a key role in the pathophysiology of the disease. Controlled studies in support of this hypothesis, however, have been both scanty and almost confined to children12,13 or to patients with MCD who were evaluated in the context of a retrospective, observational design.14 Indeed, less attention was given to adults and patients with FSGS given difficulties in designing adequately powered trials.Here, we designed a longitudinal, off-on study (ClinicalTrials.gov #) to evaluate the efficacy of rituximab in reducing the incidence of relapses and need for steroid and other immunosuppressive medications in children and adults with steroid-dependent or frequently relapsing NS due to MCD, MesGN, or FSGS. To minimize the side effects and costs of rituximab, we abandoned the standard four-dose protocol originally implemented for the treatment of B-cell lymphomas, NCT0098183815 and adopted a new B cell–driven regimen we found to achieve remission of NS in patients with idiopathic membranous nephropathy (IMN) as effectively as the standard protocol, but with fewer side effects and less costs.16 相似文献
37.
Mascolo N Mereto E Borrelli F Orsi P Sini D Izzo AA Massa B Boggio M Capasso F 《Digestive diseases and sciences》1999,44(11):2226-2230
Current evidence suggests that aberrant cryptfoci (ACF) can be used to evaluate agents for theirpotential colon carcinogenic activity. The aim of thepresent study was to determine whether senna pod extract (SE) itself induces ACF and tumors in the ratcolon or increases the development of ACF and tumorsinduced by azoxymethane (AOM). A daily administration ofSE 10 mg/kg by mouth for 13-28 weeks produced a weak laxative effect but did not itself causethe appearance of ACF or tumors. The numbers of ACF andtumors induced by AOM were, however, increased by a doseof SE (100 mg/kg) able to induce chronic diarrhea over three months. These resultssuggest that SE does not cause the appearance of ACF ortumors in the rat colon nor does it have a promotingeffect when given to rats at a dose that produceslaxation (10 mg/kg), whereas a diarrhogenic dose (100mg/kg) increases the appearance of tumors induced byAOM. 相似文献
38.
Antonio Solazzo Luigi Monaco Lucia Del Vecchio Alfonso Reginelli Francesca Iacobellis Raffaella Capasso Stefania Tamburrini Daniela Berritto Maria Rosaria Barillari Maria Rosaria Monsurrò Natale Di Martino Roberto Grassi 《Dysphagia》2014,29(5):539-544
The aim of this study was to find whether there are manometric pharyngeal changes that may have diagnostic and prognostic relevance in the amyotrophic lateral sclerosis (ALS) patient who does not show changes in contrast-medium oropharyngeal transit in a videofluoroscopic swallowing study. Ten ALS patients, with an ALS Severity Scale Score of at least 7, no need to change dietary habit, no aspiration and/or penetration, and no other changes in contrast-medium oropharyngeal transit, were collected from our institution’s database of videofluoromanometric swallowing studies. They were included in the study together with a group of 11 healthy volunteers. For each subject, 12 manometric items—7 for the pharyngeal phase and 5 for UES functionality—were evaluated. Statistically significant differences between the ALS patients and the healthy volunteers were found for pharyngeal contraction time of the upper region (median = 1,120, range = 880–1,420 vs. median = 970, range = 800–1,140), pharyngeal contraction time of the intermediate region (median = 1140, range = 960–1,360 vs. median = 770, range = 280–1,180), pharyngeal contraction time of the lower region (median = 1,320, range = 920–1,760 vs. median = 800, range = 620–1,780), and residual pressure after the relaxation of the UES (median = 2.2, range = ?20.2 to 27.8 vs. median = ?5.7, range = ?2.9 to 8.4). A videofluoromanometric swallowing study may show an increase in the pharyngeal contraction time and in residual pressure after relaxation of the UES in ALS patients without videofluoroscopic changes in contrast-medium oropharyngeal transit. 相似文献
39.